Johnson & Johnson is acquiring the biotech startup Halda Therapeutics for approximately $3.05 billion in cash. The deal, announced 17 November 2025, will provide J&J access to Halda’s innovative cancer drug pipeline.
Key details include:
- Acquisition price: Johnson & Johnson will pay $3.05 billion in cash for Halda.
- Technology: Halda specialises in a proprietary “Regulated Induced Proximity TArgeting Chimera” (RIPTAC™) platform. This technology uses a novel “hold and kill” mechanism designed to selectively target and eliminate cancer cells, which may help overcome drug resistance common with other therapies.
- Lead candidate: The primary asset in the acquisition is HLD-0915, an experimental, oral, once-daily therapy for metastatic castration-resistant prostate cancer. This treatment has shown promising results in early-stage clinical trials.
- Strategic rationale: The acquisition strengthens J&J’s oncology (cancer treatment) portfolio and helps the company bolster its pipeline of innovative medicines. The RIPTAC platform offers potential for new treatments across various solid tumour types, including breast and lung cancers.
- Timeline: The transaction is expected to close within the next few months, subject to standard closing conditions and antitrust clearance.
This move is part of an ongoing trend of large pharmaceutical companies acquiring innovative biotech firms to boost their R&D pipelines.
#pharmapress
#pharma
#pharmainnovation
